Blockchain

Zircuit Raises Mainnet Funding Round With Participation From Binance Labs, Mirana Ventures, And Others

George Town, Cayman Islands, July 22nd, 2024, Chainwire

 

Zircuit, a fully EVM-compatible ZK rollup with AI-enabled sequencer level security, today announced it raised a Mainnet funding round with participation from Binance Labs, Mirana Ventures, Amber Group, Selini, Robot Ventures, Nomad Capital, Borderless Capital, and prominent angel investors including the founders of Renzo, Etherfi, Pendle, Parallel, LayerZero, Axelar, F2Pool, Nonce, KelpDAO, ETHGlobal, Maelstrom, and more. With this new funding, Zircuit will be able to supercharge ecosystem growth and activity on its network, building upon a strong technical foundation and over $2.9 billion in staked assets.

Since 2022, the Zircuit team has built a new L2 network that introduces a revolutionary new approach to onchain security. Zircuit protects dApps and their users from blockchain vulnerabilities through its novel infrastructure that is armored by sequencer-level security and built-in, automated AI techniques to guard against smart contract exploits and malicious actors. The network’s hybrid architecture also results in a fast, low-cost, and fully EVM-compatible ZK rollup, offering unparalleled security for users without compromising speed or compatibility.

Bolstered by its strong security infrastructure, Zircuit plans to become a central hub for restaked assets that features unparalleled security and allows users to earn industry-leading yields natively. The landscape of liquid restaking is still nascent and rapidly evolving and new LRT protocols are constantly emerging, making it challenging for even experienced users to track and choose the best and the safest protocols for deploying their capital. Zircuit aims to address this problem by becoming a major liquidity hub for restaked assets (ETH, BTC, LSTs, and LRTs) where users can easily allocate their capital and have peace of mind knowing that funds are deployed to the safest and highest quality protocols.

“At Binance Labs, we support projects that are innovating in Web3 and accelerating the blockchain industry. Through its integration of sequencer level security, Zircuit is providing a more secure L2 solution and we look forward to watching it grow and develop further,” said Yi He, Co-Founder of Binance and Head of Binance Labs.

“Security has been a persistent issue in the crypto space, with breaches occurring almost daily. Zircuit, founded by top security veterans, leads the industry with its best-in-class security architecture. The team’s clear growth strategy has led to explosive growth in assets locked since launch,” said Erick Zhang, Managing Partner of Nomad Capital. “We are excited to support and continue working with the Zircuit team.”

“As the web3 space accelerates toward mainstream adoption, Zircuit will empower this growth by providing the necessary infrastructure to onboard the masses. Our years of research into rollups and blockchain security have allowed us to build an L2 network with unparalleled security and scalability. We’re proud to have the support of Binance Labs, Mirana Ventures, and our other investors as we approach our first phase of Mainnet and establish Zircuit as a cornerstone in the industry,” stated Martin Derka, co-founder of Zircuit.

Zircuit’s Mainnet Phase 1 is set to launch in the coming weeks.

To learn more about Zircuit, users can visit zircuit.com or read the developer docs at docs.zircuit.com

To participate in Build to Earn, users can visit: https://build.zircuit.com/

To participate in Zircuit Staking, users can visit: https://stake.zircuit.com/

About Zircuit 

Zircuit is a ZK rollup with AI-enabled sequencer-level security and parallelized circuits. Built by a team of web3 security veterans and PhDs in computer science, algorithms, and cryptography, Zircuit’s unique architecture combines the best of both worlds of performance and security. To learn more visit zircuit.com or follow us on Twitter/X @ZircuitL2

 

Contact

Jessica
Zircuit
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

2024-10-02T11:08:00Z

PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

  • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
  • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
  • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

Keiretsu Forum: A Global Leader in Early-Stage Innovation

Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

"Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

Event Details

  • Date: October 31, 2024
  • Time: 8:00 AM – 6:00 PM EDT
  • Location: Convene City View, 30 S 17th St, Philadelphia, PA

Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

About Keiretsu Forum :

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

About Dr. Martin Gershon

Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

For media inquiries, please contact:

Cindi Sutera
AMS Communications
[email protected]
610-613-2773


GlobeNewsWire News

Recent Comments